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Journal of the American Heart Association
SYSTEMATIC REVIEW AND META-ANALYSIS

Death and Myocardial Infarction Following
Initial Revascularization Versus Optimal
Medical Therapy in Chronic Coronary
Syndromes With Myocardial Ischemia: A
Systematic Review and Meta-Analysis of
Contemporary Randomized Controlled Trials
Andrea Soares, MD; William E. Boden, MD; Whady Hueb, MD, PhD; Maria M. Brooks, PhD;
Helen E. A. Vlachos, MS; Kevin O’Fee, MD; Angela Hardi
, MLIS; David L. Brown , MD
BACKGROUND: In chronic coronary syndromes, myocardial ischemia is associated with a greater risk of death and nonfatal
myocardial infarction (MI). We sought to compare the effect of initial revascularization with percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG) plus optimal medical therapy (OMT) with OMT alone in patients with chronic
coronary syndrome and myocardial ischemia on long-term death and nonfatal MI.
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METHODS AND RESULTS: Ovid Medline, Embase, Scopus, and Cochrane Library databases were searched for randomized
controlled trials of PCI or CABG plus OMT versus OMT alone for patients with chronic coronary syndromes. Studies were
screened and data were extracted independently by 2 authors. Random-effects models were used to generate pooled
treatment effects. The search yielded 7 randomized controlled trials that randomized 10 797 patients. Median follow-up was
5 years. Death occurred in 640 of the 5413 patients (11.8%) randomized to revascularization and in 647 of the 5384 patients
(12%) randomized to OMT (odds ratio [OR], 0.97; 95% CI, 0.86–1.09; P=0.60). Nonfatal MI was reported in 554 of 5413 patients (10.2%) in the revascularization arms compared with 627 of 5384 patients (11.6%) in the OMT arms (OR, 0.75; 95%
CI, 0.57–0.99; P=0.04). In subgroup analysis, nonfatal MI was significantly reduced by CABG (OR, 0.35; 95% CI, 0.21–0.59;
P<0.001) but was not reduced by PCI (OR, 0.92; 95% CI, 0.75–1.13; P=0.43) (P-interaction <0.001).
CONCLUSIONS: In patients with chronic coronary syndromes and myocardial ischemia, initial revascularization with PCI or
CABG plus OMT did not reduce long-term mortality compared with OMT alone. CABG plus OMT reduced nonfatal MI compared with OMT alone, whereas PCI did not.
Key Words: coronary artery bypass grafting ■ coronary artery disease ■ myocardial ischemia ■ percutaneous coronary intervention

I

schemic heart disease, which includes the acute coronary syndromes and chronic coronary syndromes
(CCS), is the leading cause of death and years of lost
life in adults worldwide.1,2 Annually, ≈1 in 30 patients

with CCS, also referred to as stable coronary artery
disease (CAD) or stable ischemic heart disease, will
experience cardiovascular death or myocardial infarction (MI),3 generally caused by the transition to an
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CLINICAL PERSPECTIVE

ISCHEMIA-CKD

What Is New?

• This updated systematic review and metaanalysis of randomized controlled trials of patients with chronic coronary syndromes and
inducible myocardial ischemia included studies
comparing percutaneous coronary intervention
plus medical therapy versus medical therapy
alone and coronary artery bypass grafting plus
medical therapy versus medical therapy alone
as well as studies that enrolled patients with
chronic kidney disease and severely reduced
left ventricular function.
• At a median follow-up of 5 years, initial revascularization with percutaneous coronary intervention or coronary artery bypass grafting plus
medical therapy did not reduce death compared with medical therapy alone.
• Coronary artery bypass grafting plus medical
therapy reduced nonfatal myocardial infarction
compared with medical therapy alone, whereas
percutaneous coronary intervention did not.

What Are the Clinical Implications?
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• For most patients with chronic coronary syndromes but without left main coronary disease or
severely reduced left ventricular function, shared
decision-making about revascularization should
be based on discussions of symptom relief and
quality of life and not about reduction in mortality.
• For patients in whom reduction in myocardial
infarction is a predominant concern, coronary
artery bypass grafting plus medical therapy is
superior to medical therapy alone and to percutaneous coronary intervention plus medical
therapy.

Nonstandard Abbreviations and Acronyms
BARI 2D
CCS
COURAGE

FAME 2

FFR
ISCHEMIA

Bypass Angioplasty
Revascularization 2 Diabetes
chronic coronary syndrome
Clinical Outcomes Using
Revascularization and
Aggressive Drug Evaluation
Fractional Flow Reserve
Versus Angiography for
Multivessel Evaluation 2
fractional flow reserve
International Study of
Comparative Health
Effectiveness With Medical
and Invasive Approaches

MASS II
OMT
STICH

International Study of
Comparative Health
Effectiveness With Medical
and Invasive Approaches–
Chronic Kidney Disease
Medicine, Angioplasty, or
Surgery Study II
optimal medical therapy
Surgical Treatment for
Ischemic Heart Failure

acute coronary syndrome, in particular ST-segment–
elevation MI.4 A primary goal of treatment of CCS is to
prevent death and MI.
Ischemia in CCS may occur in the presence or
absence of obstructive CAD involving the epicardial
coronary arteries.5 Because of the strong association of ischemia on stress testing with an increased
risk of death or MI, the presence of myocardial ischemia in patients found to have obstructive CAD, even
in the absence of angina, often triggers referral for
elective revascularization,6–9 with the theoretical goal
of preventing MI and reducing downstream mortality.
However, contemporary randomized controlled trials
(RCTs) of initial percutaneous coronary intervention
(PCI)–based revascularization plus optimal medical
therapy (OMT) versus OMT alone have never demonstrated a reduction in death or MI in patients assigned
to PCI. One explanation for the lack of benefit from
PCI in earlier trials is that not all patients in those trials had documented ischemia or its surrogate, an
abnormal fractional flow reserve (FFR). In theory, the
absence of a requirement for documented ischemia
might have allowed enrollment of patients at too
low risk to benefit from PCI. However, in a prior meta-analysis of 5 clinical trials enrolling a total of 5286
patients with CCS and myocardial ischemia, determined by stress testing or FFR, PCI in combination
with OMT did not demonstrate a significant reduction
in mortality or nonfatal MI compared with OMT alone,
suggesting that the association between ischemia
and death or nonfatal MI is not causal.10 However,
that meta-analysis did not include RCTs of patients
with ischemia who were randomized to coronary artery bypass grafting (CABG) in combination with OMT
versus OMT alone. CABG is an important revascularization modality for which improved survival and
reductions in new MI have been consistently demonstrated in CCS.11 It also included studies in which the
angiographic anatomical features were defined before
enrollment, which may have resulted in patients with
high-risk anatomical features not being enrolled. The
recently published ISCHEMIA (International Study of
Comparative Effectiveness With Medical and Invasive
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Approaches) trial12 randomized 5179 CCS patients
with moderate to severe ischemia to an invasive strategy consisting of PCI, CABG, or no revascularization,
as indicated, with OMT versus OMT alone after left
main CAD was ruled out and obstructive epicardial
disease was demonstrated on coronary computed
tomography angiography. Its design addressed potential shortcomings of earlier studies in that enrollment required moderate to severe ischemia on stress
testing, randomization was performed before coronary angiography, and complete revascularization
was the goal with either PCI or CABG. Nevertheless,
the study was underpowered to assess the impact
of an invasive strategy on death or nonfatal MI. Given
this important new study, we performed an updated,
study-level meta-analysis that included the ISCHEMIA
trial as well as other studies that included revascularization using PCI or CABG to determine the long-term
impact of revascularization on death and nonfatal MI
in patients with CCS, obstructive CAD, exclusive of
left main CAD, and myocardial ischemia.

METHODS
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The data that support the findings of this study are
available from the corresponding author on reasonable
request. We performed a systematic review and metaanalysis, reported according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines.13 The protocol was registered with PROSPERO
(International Prospective Register of Systematic
Reviews) (registration No. CRD42020158821).

Search Strategy
The published literature was searched using strategies implemented by a medical librarian using search
terms stable coronary artery disease, stable angina,
percutaneous coronary intervention, coronary artery
bypass graft surgery, medical therapy, and combinations of these terms. These strategies were executed
in Ovid-Medline 1946-, Embase 1947-, Scopus 1923-,
the Cochrane Library, and Clini
caltr
ials.gov. Results
were limited to RCTs by using filters recommended
by the Cochrane Group for Ovid-Medline,14 Embase,15
and a librarian-created filter for Scopus.16 All searches
were completed in April 2020. Search strategies can
be found in Data S1.

Inclusion Criteria
For inclusion, studies were required to be prospective, randomized trials of revascularization (PCI or
CABG) plus OMT versus OMT alone in patients with
CCS and epicardial obstructive CAD, with the individual outcomes of all-cause death and nonfatal MI

OMT in Chronic Coronary Syndromes

reported. Studies with 3-way randomizations to PCI
plus OMT versus CABG plus OMT versus OMT alone
were included. To reflect more contemporary interventional and medical practice, inclusion required
stent implantation in at least 50% of PCI procedures
and use of a statin in at least 50% of patients. Finally,
myocardial ischemia or abnormal FFR had to be
documented in all patients before randomization.
Studies of stable patients following a completed MI
were excluded.

Data Extraction
For studies in which all patients had either myocardial
ischemia on stress testing or an abnormal FFR,17 patient characteristics, study design, and outcomes were
systematically reviewed and recorded independently
by 2 authors (A.S. and D.L.B.). For studies in which not
all patients were required to have ischemia on stress
testing,18–20 the primary authors were contacted and
provided data on the subset of patients with ischemia
at the time of randomization. The data set for the STICH
(Surgical Treatment for Ischemic Heart Failure) trial21
was obtained on request from the Biologic Specimen
and Data Repository Information Coordinating Center
of the National Heart, Lung, and Blood Institute under
a data use agreement. Only patients who had an ischemic response on dobutamine stress echocardiography or a radionuclide stress test within 90 days of
randomization and before surgical revascularization
were included. The Washington University Human
Research Protection Office granted this study an exemption from Institutional Review Board oversight because of the deidentified nature of the data.
The risk of bias was evaluated according to the criteria of Jadad,22 including verification of randomization, blinding of investigators and patients to treatment
allocation, and description of patients who withdrew.

Outcomes
The following clinical outcomes were analyzed: death
from any cause and nonfatal MI. End point definitions
were those used in the individual trials. The definition
of nonfatal MI varied and became more precise in the
more recent studies, with the diagnosis generally requiring appropriate symptoms, biomarker elevation,
and/or electrocardiographic changes. Nonfatal postprocedural MI was included as a nonfatal MI outcome.
Definitions of MI for each study are included in Data S1.

Statistical Analysis
As individual patient-level data were only available
from one trial,21 a study-level meta-analysis of summary statistics from individual trials was performed
using Comprehensive Meta Analysis software,
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version 2 (Biostat, Englewood, NJ). Data were analyzed according to the intention-to-treat principle.
The presence of statistically significant betweenstudy heterogeneity that exceeds that expected by
chance alone was assessed by the Q statistic (significant at P<0.10), and the extent of any observed
between-study heterogeneity was determined by the
I2 (ranging from 0%–100%). Because the absence
of statistical heterogeneity does not guarantee clinical homogeneity, summary odds ratios (ORs) for all
end points were calculated with the inverse variance
method using a random-effects model from the ORs
and 95% CIs for each end point in each study. The
random-effects model provides a more conservative summary estimate because it incorporates both
within-trial and between-trial variance. Except for the
Q statistic, P<0.05 was considered statistically significant, and all tests were 2 sided.
Potential associations of treatment effect with
study-level variables were examined in subgroup
analyses. Studies in which revascularization was performed exclusively or predominantly with PCI were
compared with studies in which revascularization was
performed exclusively by CABG. In addition, studies
in which all randomized patients had ischemia were
compared with studies in which only a subset of patients had ischemia before randomization. Subgroups
were compared using a mixed effects analysis in which
a random effects model is used to combine studies
within each subgroup and a fixed effect model is used
to combine subgroups and yield the overall effect.
444 Embase arcles

288 Medline arcles

Sensitivity analyses were performed for each outcome to determine whether any single study disproportionately influenced the pooled estimate by excluding
individual trials one at a time and recalculating the
combined OR for the remaining studies. In addition,
the data for nonfatal MI were analyzed using the less
restrictive secondary definition of MI (Data S1) in the
ISCHEMIA12 and ISCHEMIA-CKD (International Study
of Comparative Health Effectiveness With Medical and
Invasive Approaches–Chronic Kidney Disease)23 trials.
Because the number of studies was <10 for both
mortality and nonfatal MI end points, a funnel plot assessment for publication bias was not performed as
the power of the tests is too low to distinguish chance
from actual asymmetry.24

RESULTS
Literature Search
The electronic search yielded 947 unique citations,
which were screened by reviewing the title or abstract
of each. Of these, 98 publications were reviewed in full
and 7 trials were included in the meta-analysis (Figure 1).
These were MASS II (Medicine, Angioplasty, or Surgery
Study II),18 COURAGE (Clinical Outcomes Using
Revascularization and Aggressive Drug Evaluation),19
BARI 2D (Bypass Angioplasty Revascularization 2
Diabetes),20 STICH,21 FAME 2 (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation 2),17
ISCHEMIA,12 and ISCHEMIA-CKD23 (Table 1). BARI 2D

321 Scopus arcles

213 Cochrane Library

112 ClinicalTrials.gov

1266 Total arcles

947 Unique citaons

432 Duplicates

98 Arcles screened for more
detailed evaluaon

849 Did not meet inclusion criteria based on tle
and abstract review

46 Full-text arcles assessed for
eligibility

39 Full-text arcles excluded
17 Studies were substudies or late follow-up of
included studies
6 Studies had <50% stent use
5 Studies or substudies including paents within
1 week of myocardial infarcon
5 Studies had <50% stan use at baseline
5 Arcles were not original research, or were
defined as editorials and review arcles
1 Study with paents with reversible ischemia
excluded

7 Studies included in quantitave
synthesis

Figure 1. Study selection.
Flow diagram depicts study selection for inclusion in the meta-analysis, according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement for reporting systematic reviews and meta-analyses.
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consisted of 2 embedded trials, a randomized trial of
PCI plus OMT versus OMT alone and a separate randomization to CABG plus OMT versus OMT alone.20
MASS II included a single 3-way randomization to
CABG plus OMT, PCI plus OMT, or OMT alone.18 The
100 patients in the OMT arm were compared separately with the PCI and CABG arms. The 7 trials enrolled patients between 1997 and 2018. All studies
excluded patients with left main stenosis of ≥50%. The
stress testing modalities and the criteria used to diagnose ischemia are presented in Table 1. The median
follow-up of the 7 trials was 5 years.
Of 10 797 patients with myocardial ischemia at the
time of randomization on the basis of stress testing or
the presence of at least 1 hemodynamically significant
coronary stenosis by FFR, 5413 were randomized to
revascularization plus OMT and 5384 were randomized to OMT alone. Baseline characteristics of the study
populations are presented in Table 2. Patients enrolled
in the studies were predominantly men. Patients with
diabetes mellitus comprised 26% to 100% of the
study populations, and 16% to 75% had experienced
a prior MI. Mean ejection fractions ranged from 26%
to 67%. OMT included aspirin, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins. All studies allowed crossover
from OMT to PCI or CABG for refractory symptoms
at the discretion of the treating physician. Unplanned
revascularization occurred in 19% to 51% of patients
in OMT arms related to crossover for treatment of refractory symptoms and in 3.9% to 35% of patients in
revascularization arms for progression of disease, graft
failure, or restenosis at the site of PCI. Drug-eluting
stent use ranged from 0% in early studies to 100% in
more contemporary studies (Table 2).
The risk of bias, as assessed by the Jadad criteria,22 is summarized in Table 3. None of the trials was
blinded. All of the studies were randomized and reported on study withdrawals and the completeness of
follow-up. All studies used an independent committee
to adjudicate end points.

Quantitative Outcomes
Of the 1287 deaths in the 10 797 randomized patients
with ischemia, 640 occurred in the 5413 patients
(11.8%) randomized to revascularization plus OMT,
whereas 647 occurred in the 5384 patients (12%)
randomized to OMT alone. The OR for revascularization plus OMT versus OMT alone for mortality was 0.97
(95% CI, 0.86–1.09; P=0.60; Q=6.5; P=0.60; I2=0%)
(Figure 2).
Nonfatal MI was reported in 554 of 5413 patients
(10.2%) in the revascularization arms compared with
627 of 5384 patients (11.6%) in the OMT arms of
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randomized trials. The OR for nonfatal MI for revascularization compared with initial OMT was 0.75 (95%
CI, 0.58–0.99; P=0.04; Q=25.8; P=0.001; I2=69%)
(Figure 3A).

Subgroup Analyses
For mortality, subgroup analysis comparing studies in
which revascularization was exclusively or predominantly with PCI (OR, 1.00; 95% CI, 0.87–1.14; P=0.95;
Q=3.13; P=0.68; I2=0%) compared with studies
in which revascularization was by CABG only (OR,
0.81; 95% CI, 0.59–1.13; P=0.22; Q=2.08; P=0.35;
I2=3.9%) demonstrated no significant reduction by
either modality and no difference in the effect of each
modality on mortality (P-interaction=0.26). For nonfatal MI, subgroup analysis indicated that there was
no significant reduction from PCI plus OMT compared with OMT alone (OR, 0.92; 95% CI, 0.75–1.13;
P=0.43; Q=10.8; P=0.06; I2=54%). However, nonfatal
MI was significantly reduced in studies in which the
revascularization arm was limited to studies of patients who exclusively underwent CABG (OR, 0.35;
95% CI, 0.21–0.59; P<0.001; Q=0.74; P=0.69; I2=0%)
(Figure 3B). The overall effect of CABG on nonfatal
MI differed significantly from that of PCI (P-interaction
<0.001). There was no significant difference in death
or nonfatal MI in the subgroup of studies requiring
ischemia or abnormal FFR for enrollment, FAME 2,17
ISCHEMIA,12 and ISCHEMIA-CKD23 trials, compared
with the remainder of studies in which stress testing
was not universal and ischemia was not required for
enrollment (data not shown).

Sensitivity Analyses
Sensitivity analysis to assess the potential impact of
qualitative differences in study design and patient
selection showed that exclusion of any single trial
(including the largest trial, ISCHEMIA trial12; the only
trial that enrolled patients with severely reduced left
ventricular ejection fraction, STICH trial21; and the
only trial that enrolled patients with chronic kidney
disease, ISCHEMIA-CKD trial23) from the analysis for
mortality or nonfatal MI did not alter the overall findings of the analysis (data not shown). When the secondary definition of MI was used for the ISCHEMIA12
and ISCHEMIA-CKD23 trials, revascularization did
not significantly reduce nonfatal MI (OR, 0.83; 95%
CI, 0.61–1.11; P=0.21; Q=33; P<0.001; I2=76%)
(Figure 3C). However, consistent with the findings
using the primary definition of MI, CABG significantly
reduced nonfatal MI (OR, 0.35; 95% CI, 0.21–0.59;
P<0.001; Q=0.74; P=0.69, I2=0%), whereas PCI did
not (OR, 1.09; 95% CI, 0.90–1.33; P=0.37; Q=10.7;
P=0.06; I2=53%) (P-interaction <0.001) (Figure 3D).
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Years of
Enrollment

1997–2001

1999–2004

2001–2005

2002–2007

Study, Country or
Region

18

MASS II, Brazil

COURAGE,19 North
America

BARI 2D,20 North
and South America,
Europe

STICH,21 North and
South America,
Europe, Asia
Stable CAD,
NYHA class II to IV
symptoms, LVEF
<35%, coronary
anatomy amenable to
CABG

Type 2 diabetes
mellitus and CAD
documented on
angiography (≥50%
stenosis of a major
epicardial vessel
associated with a
positive stress test or
classic angina)

Stable CAD and
CCS class IV angina
(medically stabilized)
At least 70% stenosis
in at least 1 epicardial
coronary artery and
objective evidence of
ischemia or at least 1
coronary stenosis of at
least 80% and classic
angina on provocative
testing

Angiographically
documented proximal
multivessel coronary
stenosis of >70% by
visual assessment and
documented ischemia
(stress testing or CCS
class)

Inclusion Criteria

CCS class III or IV angina,
left main stenosis >50%,
valvular disease requiring
repair or replacement,
cardiogenic shock (<72 h
of randomization), planned
PCI, MI within 30 d, history
of >1 prior cardiac operation,
noncardiac illness with life
expectancy <3 y, refractory
potentially lethal ventricular
arrhythmia, prior heart, lung,
kidney, or liver transplant

Required immediate
revascularization, creatinine
>2.0 mg/dL, hemoglobin A1C
>13.0%, class III or IV heart
failure, prior PCI or CABG; left
main stenosis >50%

Persistent CCS class IV
angina; markedly positive
stress test (substantial
ST-segment depression or
hypotensive response during
stage 1 of Bruce protocol);
refractory heart failure or
cardiogenic shock; LVEF
<30%, revascularization in
the prior 6 mo, coronary
anatomical features not
suitable for revascularization;
left main disease ≥50%

Refractory angina or acute MI,
ventricular aneurysm, LVEF
<40%, a history of PCI or
CABG, single-vessel disease,
and normal or minimal CAD;
left main disease ≥50%

Exclusion Criteria
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Table 1. Characteristics of Included Trials

Exercise or
pharmacologic stress
with radionucleotide
imaging, or
dobutamine stress
echocardiogram

Treadmill testing,
exercise or
pharmacologic stress
imaging (nuclear or
echocardiographic
imaging)

Treadmill testing,
exercise or
pharmacologic stress
imaging (nuclear or
echocardiographic
imaging)

Treadmill
electrocardiographic
testing

Techniques for
Detection of
Myocardial Ischemia

Summed difference score of >4 between
stress and rest (or viability if available)
images using a 17-segment model of the
LV on radionuclide stress or worsening
systolic wall thickening in >2/16 LV
segments during infusion of dobutamine
compared with baseline or prior dose

>1-mm horizontal ST-segment
depression or down-sloping ST-segment
depression or elevation for >60–80 ms
after the end of the QRS complex;
myocardial perfusion defect; myocardial
wall motion abnormality; decline in
ejection fraction with stress; Doppler or
pressure wire showing coronary flow
reserve <2.0 or fractional flow reserve
<0.75

Any of: >1-mm ST deviation on standard
treadmill exercise electrocardiography;
≥1 scintigraphic perfusion defects
during exercise 99mtechnetium sestamibi
or thallium imaging; ≥1 perfusion
defects (reversible or partial reversible)
with pharmacologic (dipyridamole,
adenosine) stress during 99mtechnetium
sestamibi or thallium imaging; >1 wall
motion abnormalities during exercise
radionuclide ventriculography or
2-dimensional echocardiography
(exercise or dobutamine)

Clinical (angina) and/or
electrocardiographic (magnitude of
horizontal or down-sloping ST-segment
depression) and/or scintigraphic (severity
and extent of the perfusion defects)

Criteria for Diagnosis of Ischemia

1212/255

2368/1326

2287/1938

611/344

No. of
Participants
Total/With
Ischemia

(Continued)

10

5

5

10

Follow-Up, y

Soares et al
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2010–2012

2012–2018

2014–2018

FAME 2,17 Europe and
North America

ISCHEMIA,12 North
and South America,
Europe, Asia

ISCHEMIA-CKD,23
North and South
America, Europe, Asia
CAD with moderate
to severe ischemia
on an exercise or
pharmacologic stress
test, ESRD on dialysis
or eGFR <30 mL/min
per 1.73 m2

Stable CAD with
moderate to severe
ischemia (>50%
stenosis in a major
epicardial vessel in
patients with a positive
stress echocardiogram
or >70% stenosis in
proximal or mid vessel
in patients with a
positive ETT

Stable CAD
considered for
PCI with at least 1
functionally significant
stenosis (fractional
flow reserve <0.80)

Inclusion Criteria

NYHA class III–IV heart
failure, unacceptable angina
despite OMT, LVEF <35%, left
main stenosis >50%, acute
coronary syndrome (<2 mo),
PCI (<1 y), stroke (<6 mo)

Patients with NYHA class III–
IV heart failure, unacceptable
angina despite OMT, LVEF
<35%, ACS (<2 mo), PCI or
CABG (<1 y), eGFR 30 mL/
min or on dialysis, left main
stenosis >50%

Patients in whom the
preferred treatment is CABG;
recent (<1 wk) MI; prior CABG;
LVEF <30%; left main stenosis
>50%

Exclusion Criteria

Exercise or
pharmacologic nuclear
(SPECT or PET),
echocardiography,
or CMR stress
testing. Exercise
electrocardiographic
testing without
imaging.

Exercise or
pharmacologic nuclear
(PET or SPECT),
echocardiography,
or CMR stress
testing. Exercise
electrocardiographic
testing without
imaging.

Fractional flow reserve

Techniques for
Detection of
Myocardial Ischemia

>10% Ischemic myocardium on
nuclear perfusion via SPECT or PET;
>3/16 segments with stress-induced
severe hypokinesis or akinesis on
echocardiography; >12% ischemic
myocardium and/or >3/16 segments
with stress-induced severe hypokinesis
or akinesis on CMR; absence of resting
ST-segment depression >1 mm or
noninterpretable ECG and additional
exercise-induced horizontal or downsloping ST-segment depression >1.5 mm
in 2 leads or >2 mm in any lead and
either workload at which ST-segment
criteria were met not exceeding
completion of stage 2 of standard Bruce
protocol or 7 METs or ST-segment
criteria met at <75% of maximum
predicted HR on exercise test without
imaging

>10% LV ischemia on nuclear testing, >3
segments of stress-induced moderate
or severe hypokinesis or akinesis, >12%
ischemic myocardium and/or wall motion
with >3/16 segments with stressinduced severe hypokinesis or akinesis,
>1.5-mm ST-segment depression in >2
leads or >2-mm ST-segment depression
in single lead at <7 METs with angina

Fractional flow reserve <0.80 during
adenosine-induced hyperemia in at least
1 major coronary artery

Criteria for Diagnosis of Ischemia

777/777

5179/5179

888/888

No. of
Participants
Total/With
Ischemia

3

5

5

Follow-Up, y

ACS indicates acute coronary syndrome; BARI 2D, Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, Canadian Cardiovascular
Society; CMR, cardiac magnetic resonance; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ETT,
exercise treadmill test; FAME 2, Fractional Flow Reserve vs Angiography for Multivessel Evaluation 2; HR, heart rate; ISCHEMIA, International Study of Comparative Health Effectiveness With Medical and Invasive
Approaches; ISCHEMIA-CKD, International Study of Comparative Health Effectiveness With Medical and Invasive Approaches–Chronic Kidney Disease; LV, left ventricle; LVEF, left ventricular ejection fraction; MASS II,
Medicine, Angioplasty, or Surgery Study II; MET, metabolic equivalent task; MI, myocardial infarction; NYHA, New York Heart Association; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; PET,
positron emission tomography; SPECT, single-photon emission computed tomography; and STICH, Surgical Treatment for Ischemic Heart Failure.

Years of
Enrollment

Study, Country or
Region

Downloaded from http://ahajournals.org by on February 22, 2022

Table 1. Continued

Soares et al
OMT in Chronic Coronary Syndromes

J Am Heart Assoc. 2021;10:e019114. DOI: 10.1161/JAHA.120.0191147

28 (28)

30 (26)

62 (4)

49 (43)

0 (0)

Diabetes
mellitus, N (%)

Prior MI, N (%)

Ejection fraction,
mean (SD or
IQR), %

Unplanned
revascularization,
N (%)

Drug-eluting
stent during
index procedure,
N (%)

90 (78)

80 (70)

ACEI or ARB

Statin

81 (68)

91 (76)

88 (74)

93 (78)

NA

12 (10)

65 (5)

32 (27)

34 (29)

85 (71)

60 (9)

119

CABG =
OMT

85 (85)

94 (94)

90 (90)

88 (88)

NA

45 (45)

67 (6)

28 (28)

35 (35)

77 (77)

59 (8)

100

OMT

MASS II CABG18

862 (89)

714 (74)

802 (83)

905 (93)

29 (3)

194 (20)

61 (11)

342 (35)

314 (32)

830 (86)

62 (10)

968

PCI +
OMT

876 (90)

705 (73)

806 (83)

898 (93)

NA

287 (30)

61 (10)

348 (36)

336 (35)

826 (85)

62 (10)

970

OMT

COURAGE19

465 (96)

456 (94)

445 (92)

467 (97)

172 (37)

137 (28)

57 (11)

125 (26)

483 (100)

353 (73)

63 (9)

483

PCI +
OMT

468 (96)

461 (94)

447 (91)

466 (95)

NA

187 (38)

57 (11)

122 (26)

489 (100)

357 (73)

62 (9)

489

OMT

163 (93)

165 (94)

160 (91)

161 (92)

NA

20 (11)

54 (12)

45 (26)

176 (100)

147 (84)

65 (8)

176

CABG +
OMT

177 (99)

174 (98)

169 (95)

175 (98)

NA

77 (43)

56 (11)

50 (29)

178 (100)

144 (81)

64 (8)

178

OMT

BARI 2D CABG20

103 (80)

119 (92)

114 (88)

108 (84)

NA

5 (4)

26 (8)

91 (71)

51 (40)

118 (92)

62 (9)

129

CABG +
OMT

106 (84)

116 (92)

112 (89)

111 (88)

NA

26 (21)

27 (9)

95 (75)

52 (41)

108 (86)

61 (10)

126

OMT

STICH21

370 (83)

308 (69)

338 (76)

390 (87)

435 (97)

60 (13)

NR

164 (37)

123 (28)

356 (80)

64 (9)

447

PCI +
OMT

361 (82)

309 (70)

344 (78)

396 (90)

NA

225 (51)

NR

165 (37)

117 (27)

338 (77)

64 (10)

441

OMT

FAME 217

2441 (94)

1685 (65)

NR

2443 (97)

1388/1418
stents
(98)

396 (15)

60 (55–65)

495 (19)

1071 (41)

1982 (77)

64 (58–70)

2588

Invasive +
OMT*

2463 (95)

1731 (67)

NR

2429 (96)

NA

544 (21)

60 (55–65)

496 (19)

1093 (42)

2029 (78)

64 (58–70)

2591

OMT

ISCHEMIA12

316 (82)

184 (48)

NR

314 (84)

146/146
stents
(100)

NR

58 (50–63)

62 (16)

226 (58)

268 (69)

62 (55–69)

388

Invasive +
OMT†

313 (81)

186 (48)

NR

302 (82)

NA

73 (19)

58 (50–64)

71 (18)

218 (56)

267 (69)

64 (56–70)

389

OMT

ISCHEMIA-CKD23

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BARI 2D, Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary artery bypass grafting;
COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; FAME 2, Fractional Flow Reserve vs Angiography for Multivessel Evaluation 2; IQR, interquartile range; ISCHEMIA, International
Study of Comparative Health Effectiveness With Medical and Invasive Approaches; ISCHEMIA-CKD, International Study of Comparative Health Effectiveness With Medical and Invasive Approaches–Chronic Kidney
Disease; MASS II, Medicine, Angioplasty, or Surgery Study II; MI, myocardial infarction; NA, not applicable; NR, not reported; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; and STICH, Surgical
Treatment for Ischemic Heart Failure.
*The invasive strategy resulted in revascularization in 79% of patients (PCI in 74% and CABG in 26%).
†
The invasive strategy resulted in revascularization in 51% of patients (PCI in 85% and CABG in 15%).

85 (85)

94 (94)

88 (88)

90 (90)

92 (80)

92 (80)

Aspirin

NA

45 (45)

67 (6)

77 (77)

β-Blocker

Medical therapy, N (%)

35 (35)

73 (63)

30 (26)

Men, N (%)

100

59 (8)

115

61 (7)

OMT

Age, mean (SD
or IQR), y

PCI +
OMT

No.

Characteristic

MASS II PCI18

BARI 2D PCI20
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Table 3. Quality Metrics of Included Studies
Study

Study Blinding

Blinding Technique

Random Assignment

Withdrawal Descriptions

MASS II

No

No

Yes

Yes

COURAGE19

No

No

Yes

Yes

18

20

No

No

Yes

Yes

STICH21

No

No

Yes

Yes

FAME 217

No

No

Yes

Yes

ISCHEMIA12

No

No

Yes

Yes

No

No

Yes

Yes

BARI 2D

ISCHEMIA-CKD

23

BARI 2D indicates Bypass Angioplasty Revascularization Investigation 2 Diabetes; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation; FAME 2, Fractional Flow Reserve vs Angiography for Multivessel Evaluation 2; ISCHEMIA, International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches; ISCHEMIA-CKD, International Study of Comparative Health Effectiveness With Medical and Invasive
Approaches–Chronic Kidney Disease; MASS II, Medicine, Angioplasty, or Surgery Study II; and STICH, Surgical Treatment for Ischemic Heart Failure.

DISCUSSION
The principal findings of this meta-analysis of RCTs
of patients with CCS who have both obstructive,
but not left main, CAD and myocardial ischemia
are 2-fold. First, a strategy of initial PCI or CABG, in
combination with OMT, resulted in no significant reduction in mortality compared with initial OMT with
crossover to revascularization, as clinically indicated,
at a median follow-up of 5 years. Second, although a
strategy of initial revascularization with PCI or CABG,
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Figure 2. Comparison of revascularization and optimal
medical therapy vs optimal medical therapy alone in
patients with chronic coronary syndromes, obstructive
coronary artery disease, and myocardial ischemia for allcause mortality during follow-up.
All included studies are shown by name along with point
estimates of the odds ratios and respective 95% CIs. The size
of the squares denoting the point estimate in each study is
proportional to the weight of the study. BARI 2D indicates Bypass
Angioplasty Revascularization Investigation 2 Diabetes; CABG,
coronary artery bypass grafting; COURAGE, Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation;
FAME 2, Fractional Flow Reserve vs Angiography for Multivessel
Evaluation 2; ISCHEMIA, International Study of Comparative
Health Effectiveness With Medical and Invasive Approaches;
ISCHEMIA-CKD, International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches–Chronic
Kidney Disease; MASS II, Medicine, Angioplasty, or Surgery
Study II; PCI, percutaneous coronary intervention; and STICH,
Surgical Treatment for Ischemic Heart Failure.

in combination with OMT, was associated with an
overall reduction in nonfatal MI, subgroup analysis
revealed that CABG plus OMT resulted in a significant reduction in nonfatal MI compared with OMT
alone, whereas PCI plus OMT did not significantly reduce nonfatal MI compared with OMT alone. To our
knowledge, this is the only meta-analysis of RCTs of
patients with CCS and objectively documented myocardial ischemia in which revascularization included
both PCI and CABG. Furthermore, it is the first metaanalysis to include patients with CCS and severely
reduced left ventricular ejection fraction as well as
those with CKD. As such, it should be of significant
interest to healthcare providers, healthcare systems,
third-party payers, and patients.
Given the profound impact of ischemic heart disease
on mortality worldwide,1 the primary goal of treatment
is to prevent death. In the setting of an acute coronary syndrome, in particular ST-segment–elevation MI,
short-term mortality is reduced by timely revascularization by PCI25 to salvage myocardium and minimize
myocyte loss; however, in the long-term setting, there
has been no conclusive evidence for an incremental
benefit of revascularization on mortality beyond that
achieved by disease-modifying OMT and lifestyle
modification. As acute MI has long been assumed to
be on the causal pathway to mortality in patients with
CCS, reducing mortality is logically dependent on preventing the progression of stable disease to acute MI.
Thus, for revascularization to favorably impact survival,
it should prevent the development of or mitigate the
consequences of MI.
In patients who undergo revascularization for
CCS, 2 types of MI are recognized,26 periprocedural
(type 4a or type 5) or spontaneous (type 1 or type
2). Type 4a MI occurs following PCI, whereas type
5 MI occurs after CABG. Spontaneous MIs are categorized by their pathophysiological characteristics
as being caused by plaque disruption and superimposed thrombosis (type 1) or by a mismatch between oxygen supply and demand (type 2). Unlike

J Am Heart Assoc. 2021;10:e019114. DOI: 10.1161/JAHA.120.0191149

Soares et al

OMT in Chronic Coronary Syndromes

Downloaded from http://ahajournals.org by on February 22, 2022

Figure 3. Comparison of revascularization and optimal medical therapy vs optimal medical therapy alone in patients
with chronic coronary syndromes, obstructive coronary artery disease, and myocardial ischemia for nonfatal myocardial
infarction (MI) during follow-up.
All included studies are shown by name along with point estimates of the odds ratios and respective 95% CIs. The size of the
squares denoting the point estimate in each study is proportional to the weight of the study. A, Comparison of revascularization
and optimal medical therapy vs optimal medical therapy alone in patients with chronic coronary syndromes, obstructive coronary
artery disease, and myocardial ischemia for nonfatal MI using the primary definition of MI from the ISCHEMIA (International Study of
Comparative Health Effectiveness With Medical and Invasive Approaches)12 and ISCHEMIA-CKD (International Study of Comparative
Health Effectiveness With Medical and Invasive Approaches–Chronic Kidney Disease)23 trials. B, Subgroup comparison of nonfatal
MI where revascularization was performed exclusively or predominantly with percutaneous coronary intervention vs studies in
which revascularization was exclusively by coronary artery bypass grafting. Nonfatal MI was defined using the primary definition in
the ISCHEMIA12 and ISCHEMIA-CKD23 trials. C, Comparison of revascularization and optimal medical therapy vs optimal medical
therapy alone in patients with chronic coronary syndromes, obstructive coronary artery disease, and myocardial ischemia for nonfatal
MI using the secondary definition of MI in the ISCHEMIA12 and ISCHEMIA-CKD23 trials. D, Subgroup comparison of nonfatal MI
where revascularization was performed exclusively or predominantly with percutaneous coronary intervention vs studies in which
revascularization was exclusively by coronary artery bypass grafting. Nonfatal MI was defined using the secondary definition in the
ISCHEMIA12 and ISCHEMIA-CKD23 trials. BARI 2D indicates Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG,
coronary artery bypass grafting; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; FAME
2, Fractional Flow Reserve vs Angiography for Multivessel Evaluation 2; MASS II, Medicine, Angioplasty, or Surgery Study II; PCI,
percutaneous coronary intervention; and STICH, Surgical Treatment for Ischemic Heart Failure.

OMT, revascularization procedures uniquely expose
patients to periprocedural MIs that result in myonecrosis, as demonstrated by cardiac magnetic resonance imaging.27 Large periprocedural MIs adversely
affect prognosis, whereas the clinical significance of
smaller type 4a or type 5 MIs is controversial. The
prevalence of periprocedural MI depends on the biomarker selected and the threshold for abnormality
used as well as the rigor of the surveillance strategy. In response to trials, such as the FAME 217 and
ISCHEMIA12 trials, in which the overall rate of MI was
similar in both invasive and OMT arms, it has been
argued that revascularization increased periprocedural Mis, which have little prognostic consequence,

but, in turn, decreased spontaneous MIs, which are
thought to be prognostically important despite any
reduction in mortality in the revascularization arms of
these trials.27
All patients with CCS are at risk for the development
of both spontaneous type 1 and type 2 MIs, which are
both associated with impaired survival, albeit by different mechanisms. Type 1 MI adversely affects survival
by causing significant myonecrosis and subsequent
scarring that may reduce left ventricular function28 and/
or contribute to a proarrhythmic substrate.29 Patients
with type 2 MIs generally experience less myonecrosis
but are at higher risk of death from noncardiovascular
than cardiovascular causes.30 Unfortunately, because
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accurate differentiation between spontaneous MI
types 1 and 2 would require invasive intracoronary imaging to directly visualize the presence of disruption
and thrombosis at the site of the culprit plaque, the
currently applied clinical and angiographic criteria are
imprecise, at best.31
Given that patients with CCS and obstructive CAD
can meet the diagnostic requirements for spontaneous type 2 MI, including chest pain, ischemic electrocardiographic changes, and troponin elevation,32
following the supply:demand mismatch intentionally
induced by a treadmill stress test, it is reasonable to
assume that PCI can reduce type 2 MI by reducing
the hemodynamic effects of an obstructive lesion on
oxygen supply during episodes of increased oxygen
demand. Because it is known that most spontaneous
type 1 MIs following PCI occur because of progression of atherosclerotic disease in non–flow-limiting
lesions anatomically distant from the originally instrumented lesion,33 it is not biologically plausible that PCI
prevents those spontaneous type 1 MIs that originate
from new plaque disruption events occurring at minimally stenotic remote coronary locations. Furthermore,
if PCI prevented more type 1 spontaneous MIs than
the periprocedural MIs it causes, mortality should be
reduced. But this analysis and all prior analyses have
failed to detect any impact of PCI on mortality.
The fact that patients with type 2 MI are at higher
risk of death from noncardiovascular causes30 may
fundamentally explain why mortality from CCS has
never been reduced by PCI in contemporary RCTs of
PCI versus OMT and meta-analyses of these studies,
despite the likely reduction in spontaneous but predominantly type 2 MI. In contrast to the mechanism
of PCI reducing the hemodynamic effect of discrete
obstructive lesions, CABG supplies an alternative conduit for oxygen delivery to the myocardium in the event
of thrombotic occlusion of the bypassed native coronary artery. It is therefore much more likely that CABG
would reduce both type 1 and type 2 MI in patients
with CCS, resulting in a significantly greater number of
MIs prevented, as shown in this study. It is also notable
that the reduction of MI in the CABG arm of the STICH
trial of patients with severely reduced left ventricular
function translated into reduced mortality at 10 years
of follow-up.21 Thus, it is reasonable to postulate that,
because patients with severely reduced left ventricular
systolic function can least well tolerate a new MI with a
further decline in ventricular function, they are the CCS
subgroup most likely to derive a mortality benefit from
CABG.
Placed in context of prior data, our results suggest
that all patients with CCS have a basal risk of type 1
and type 2 spontaneous MI that is reduced by OMT
and lifestyle modification. Revascularization with PCI
increases periprocedural MI, plausibly reduces type
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2 MI, and has minimal effect on type 1 MI, resulting
in a neutral effect on mortality. Revascularization with
CABG increases periprocedural MI, reduces type 2 MI,
and prevents or mitigates the effect of type 1 MI, with
a neutral effect on mortality in patients with preserved
left ventricular function.
The results of this study-level meta-analysis should
be interpreted in the context of certain limitations.
First, complete information on the extent and severity
of myocardial ischemia was not available for all studies, which limited analysis to patients with any degree
of objectively documented ischemia. However, the
ISCHEMIA trial did not demonstrate any relationship
between the severity and extent of ischemia and improved outcomes with revascularization.12 Second, not
all participants in MASS II,18 COURAGE,19 BARI 2D,20
and STICH21 underwent stress testing. Although those
who did undergo stress testing may not have been
representative of the entire study population, their outcomes mirrored those of the entire study populations.
Third, we limited our analysis to relatively bias-resistant
outcomes and did not include angina as an end point
in this meta-analysis as recent data suggest the impact
of PCI on angina relief may be partially attributed to
a placebo effect,34 and none of the studies included
was blinded to treatment assignment. Fourth, although
there have been improvements in stent technology
over the past 2 decades that may induce heterogeneity in results over time, no mortality difference has been
demonstrated between bare metal and drug-eluting
stents.35 Fifth, we could not determine the revascularization modality-specific outcomes of patients in the
ISCHEMIA12 and ISCHEMIA-CKD23 trials who underwent PCI or CABG. However, inclusion of the small
percentage of patients who underwent CABG in both
studies in the PCI subgroup would bias the nonfatal MI
results in favor of PCI. Sixth, we did not have access
to individual patient data from the RCTs included, except for the STICH trial. Thus, our ability to examine the
impact of randomized treatment assignment on many
subgroups was limited. Finally, data were extracted
only from RCTs that may not be representative of the
unselected patients seen in daily clinical practice.
In summary, in patients with CCS, obstructive CAD,
exclusive of significant left main CAD, and objective
evidence of myocardial ischemia, an initial strategy of
revascularization with PCI or CABG and OMT does
not reduce mortality compared with a strategy of initial
OMT alone with crossover to revascularization as necessary for refractory symptoms. Although there was
a significant reduction in nonfatal MI among patients
who underwent CABG plus OMT, PCI combined with
OMT did not confer a benefit in reducing MI compared
with OMT alone, which supports a mechanistic difference in the type of revascularization performed and its
impact on MI.
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Thus, for most patients with CCS but without left
main CAD, shared decision-making about revascularization should be based on discussions of symptom
relief and quality of life. For patients in whom reduction
in MI is an overarching goal, such as those with severely reduced left ventricular ejection fraction, CABG
plus medical therapy is superior to OMT alone and to
PCI plus OMT.
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Data S1.

Search Strategy

Embase.com
('stable coronary artery disease'/exp OR ('coronary artery disease'/exp AND stable:ti,ab,kw) OR
('coronary artery disease'/de AND stable:ti,ab,kw) OR (stable NEAR/3 (‘coronary disease*’ OR
‘coronary artery disease*’ OR ‘coronary atherosclerosis’ OR ‘coronary heart disease*’)))
AND
(('percutaneous coronary intervention'/exp OR 'coronary artery bypass graft'/exp) OR
(‘percutaneous coronary intervention*’ OR ‘percutaneous coronary angioplast*’ OR ‘balloon
angioplasty’ OR ‘coronary angioplasty’ OR ‘PCI’ OR ‘percutaneous coronary
revascularization*’ OR ‘coronary artery bypass*’ OR ‘coronary artery bypass graft*’ OR
‘coronary bypass graft*’ OR ‘coronary vein bypass*’ OR ‘coronary venous bypass graft*’ OR
‘aortocoronary bypass*’ OR ‘aortocoronary anastomosis’ OR ‘CABG’):ti,ab,kw)
AND
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(drug therapy'/de OR (‘medical therap*’ OR ‘medical-therap*’ OR ‘drug therapy’ OR ‘non
surgical’ OR ‘diet’ OR ‘exercise’ OR ‘lifestyle intervention’):ti,ab,kw)
AND
('clinical trial'/de OR 'randomized controlled trial'/de OR 'randomization'/de OR 'single blind
procedure'/de OR 'double blind procedure'/de OR 'crossover procedure'/de OR 'placebo'/de OR
'prospective study'/de OR 'randomi?ed controlled' NEXT/1 trial* OR rct OR 'randomly allocated'
OR 'allocated randomly' OR ‘randomized trial’ OR 'random allocation' OR allocated NEAR/2
random OR single NEXT/1 blind* OR double NEXT/1 blind* OR (treble OR triple) NEAR/1
blind* OR placebo*)
Ovid-Medline
((Coronary Artery Disease/ AND stable.ti,ab.) OR (Coronary Disease/ AND stable.ti,ab.) OR
(stable.mp. ADJ3 ("coronary disease*".mp. OR "coronary artery disease*".mp. OR "coronary
atherosclerosis".mp. OR "coronary heart disease*".mp.)))
AND
((exp Percutaneous Coronary Intervention/ OR exp Coronary Artery Bypass/) OR
("percutaneous coronary intervention*" OR "percutaneous coronary angioplast*" OR "balloon
angioplasty" OR "coronary angioplasty" OR "PCI" OR "percutaneous coronary
revascularization*" OR "coronary artery bypass*" OR "coronary artery bypass graft*" OR

"coronary bypass graft*" OR "coronary vein bypass*" OR "coronary venous bypass graft*" OR
"aortocoronary bypass*" OR "aortocoronary anastomosis" OR "CABG").ti,ab.)
AND
Combined Modality Therapy/ OR Drug Therapy/ OR ("medical therap*" OR "medical-therap*"
OR "drug therapy" OR "non surgical" OR diet OR exercise OR "lifestyle intervention").ti,ab.)
AND
(randomized controlled trial.pt. OR controlled clinical trial.pt. OR randomized.ab. OR
placebo.ab. OR drug therapy.fs. OR randomly.ab. OR trial.ab. OR groups.ab.)
Scopus
(TITLE-ABS-KEY(stable W/3 “coronary disease*”) OR TITLE-ABS-KEY(stable W/3
“coronary artery disease*”) OR TITLE-ABS-KEY(stable W/3 “coronary atherosclerosis”) OR
TITLE-ABS-KEY(stable W/3 “coronary heart disease”) OR TITLE-ABS-KEY(stable W/3
“coronary disease*”))
AND
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TITLE-ABS-KEY("percutaneous coronary intervention*" OR "percutaneous coronary
angioplast*" OR "balloon angioplasty" OR "coronary angioplasty" OR "PCI" OR "percutaneous
coronary revascularization*" OR "coronary artery bypass*" OR "coronary artery bypass graft*"
OR "coronary bypass graft*" OR "coronary vein bypass*" OR "coronary venous bypass graft*"
OR "aortocoronary bypass*" OR "aortocoronary anastomosis" OR "CABG")
AND
TITLE-ABS-KEY("medical therap*" OR "medical-therap*" OR "drug therapy" OR "non
surgical" OR diet OR exercise OR "lifestyle intervention")
AND
( INDEXTERMS ( "clinical trials" OR "clinical trials as a topic" OR "randomized controlled
trial" OR "Randomized Controlled Trials as Topic" OR "controlled clinical trial" OR "Controlled
Clinical Trials" OR "random allocation" OR "Double-Blind Method" OR "Single-Blind Method"
OR "Cross-Over Studies" OR "Placebos" OR "multicenter study" OR "double blind procedure"
OR "single blind procedure" OR "crossover procedure" OR "clinical trial" OR "controlled study"
OR "randomization" OR "placebo" ) ) OR ( TITLE-ABS-KEY ( ( "clinical trials" OR "clinical
trials as a topic" OR "randomized controlled trial" OR "Randomized Controlled Trials as Topic"
OR "controlled clinical trial" OR "Controlled Clinical Trials as Topic" OR "random allocation"
OR "randomly allocated" OR "allocated randomly" OR "Double-Blind Method" OR "SingleBlind Method" OR "Cross-Over Studies" OR "Placebos" OR "cross-over trial" OR "single blind"
OR "double blind" OR "factorial design" OR "factorial trial" ) ) ) OR ( TITLE-ABS ( clinical
trial* OR trial* OR rct* OR random* OR blind* ) )
Cochrane Library

(((stable NEAR/2 “coronary disease*”) OR (stable NEAR/2 “coronary artery disease*”) OR
(stable NEAR/2 “coronary atherosclerosis”) OR (stable NEAR/2 “coronary heart
disease”))):ti,ab,kw
AND
(("percutaneous coronary intervention*" OR "percutaneous coronary angioplast*" OR "balloon
angioplasty" OR "coronary angioplasty" OR "PCI" OR "percutaneous coronary
revascularization*" OR "coronary artery bypass*" OR "coronary artery bypass graft*" OR
"coronary bypass graft*" OR "coronary vein bypass*" OR "coronary venous bypass graft*" OR
"aortocoronary bypass*" OR "aortocoronary anastomosis" OR "CABG")):ti,ab,kw
AND
((“medical therap*” OR “medical-therap*” OR “drug therapy” OR “non surgical” OR diet OR
exercise OR “lifestyle intervention”)):ti,ab,kw

Definitions of Nonfatal Myocardial Infarction (MI) in the Included Trials
MASS II
MI was defined as the presence of significant new Q waves in at least two electrocardiographic
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(ECG) leads or symptoms compatible with MI associated with creatine kinase (CK), MB fraction
concentrations that were more than three times the upper limit of the reference range
COURAGE
The prespecified definition of MI (whether periprocedural or spontaneous) required a clinical
presentation consistent with an acute coronary syndrome and either new abnormal Q waves in
two or more electrocardiographic leads or positive results in cardiac biomarkers. Silent MI, as
detected by abnormal Q waves, was confirmed by a core laboratory and was also included as an
outcome of MI.
BARI 2D
The MI criteria used were modified from the universal MI definition in that a two-fold elevation
of abnormal biomarker profile above the upper limits of normal was used rather than the 99th

percentile. When cardiac troponin and CK-MB were simultaneously acquired, cardiac troponin
took precedence over CK-MB in establishing the diagnosis. MI was confirmed if abnormal
cardiac biomarkers occurred and there was evidence of angina or angina equivalent symptoms,
or ECG or imaging evidence of new myocardial ischemia. Cardiac biomarkers were not routinely
collected after coronary revascularization. When they were collected, a 3-fold elevation in
CKMB following a PCI procedure and a 10-fold increase in CK-MB following coronary bypass
surgery were used as the cut-points to define abnormality.
STICH
A patient must have an increase in cardiac enzymes (CK–MB greater than twice the ULN or
troponin T or I greater than three times the ULN) and at least one of the two following criteria:
Typical clinical presentation
OR
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Typical ECG changes (evolving ST-segment or T-wave changes in two or more
contiguous leads, the development of Q waves in two or more contiguous leads,
or the development of new LBBB).

An MI that occurs after a coronary bypass procedure will be adjudicated as a
STICH MI only if there are new Q-waves present and the CK-MB is
greater than 5 times the ULN and two times the pre – surgery level for CABG.
FAME 2
Within 24 hours after randomization or any PCI:
I.
CK-MB above 10 x 99th percentile upper reference limit (URL) determined on a single
measurement,
OR
II. CK-MB above 5 x 99th percentile URL determined on a single measurement PLUS at least
one of the following:

o new pathological Q waves in at least 2 contiguous leads or new persistent non-rate related left
bundle branch block (LBBB),
o angiographically documented native coronary artery occlusion,
o imaging evidence of new loss of viable myocardium
More than 24 hours after randomization:
I. Detection of rise and/or fall of cardiac biomarkers, CK-MB or troponin with at least one
value above the 99th percentile of the URL together with evidence of myocardial ischemia
with at least one of the following:
o Symptoms of ischemia
o ECG changes indicative of new ischemia (new ST-T changes or new LBBB),
OR
II. Development of pathological Q waves
in ≥ 2 contiguous precordial leads or ≥ 2 adjacent limb leads) of the ECG,
OR
Imaging evidence of loss of viable myocardium or new regional wall motion abnormality
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ISCHEMIA
Two versions of MI will be adjudicated in ISCHEMIA: a primary definition and secondary
definition. Each definition includes a hierarchy of markers and threshold values as well as a set
of rules for diagnosing MI when one or more key elements of the medical record are missing.

The Primary Definition is based upon the Universal Definition of MI, but relies upon sitereported MI decision limits for troponin (which may or may not be the same as the manufacturer
99%URL), and has selected unique marker criteria for MI after PCI or CABG (Type 4a, 5).

The Secondary Definition is also based upon the Universal Definition of Myocardial Infarction,
but specifically uses the 99%URL from the assay manufacturer’s package insert (which may or
may not be the site’s MI decision limit) and uses the same supporting criteria (eg. angiographic
and ECG) as the UMI definition.
Spontaneous MI
Marker elevation, as outlined below and at least 1 of the following:
•
•
•
•

Symptoms of ischemia, usually lasting > 20 minutes in duration
New ischemic ST and/or T wave and/or Q-wave ECG changes, or new LBBB
Imaging evidence of new loss of viable myocardium in comparison to the baseline
imaging test
Angiographic evidence of intracoronary thrombus, stent thrombosis (4b) or highgrade in-stent restenosis (≥50%) (4c)

Marker data not available and at least 2 of the following:
•
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•
•

New ischemic ST and/or T wave and/or Q-wave ECG changes, or new LBBB, as
described below
Imaging evidence of new loss of viable myocardium in comparison to the baseline
imaging test
Angiographic evidence of intracoronary thrombus.

Autopsy evidence of a fresh myocardial infarction as stand-alone criterion

Silent MI
This event includes evidence of new silent Q-wave MI detected during routine protocol or
clinically obtained ECG follow-up. Silent MI events will be classified as a type 1 MI.

Sudden death MI
MI events in which a presentation consistent with infarction is present but the patient dies before
the biomarkers are drawn or within the first few hours of the event before the biomarkers become

positive. Sudden unexpected cardiac death, including cardiac arrest, often with symptoms
suggestive of myocardial ischemia, accompanied by presumably new ST-segment elevation, or
new LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at
autopsy, but death occurring before blood samples could be obtained, or at a time before the
appearance of cardiac biomarkers in the blood.
PCI-Related MI
CK-MB is the preferred biomarker and takes precedence over troponin. For subjects with normal
baseline biomarker level pre-PCI, peri-PCI MI requires a rise in CK-MB to >5-fold the ULN (or
a rise in troponin to >35 times the MI Decision Limit/ULN, when CK- MB is unavailable) within
48 hours post-PCI. If pre-PCI cardiac markers (CKMB or cTn) are elevated, they must be stable
or falling as indicated by two samples at least 6 h apart. The post-PCI CKMB level should reflect
a rise of >20% over pre-PCI levels. In addition to biomarker criteria, peri-PCI MI requires at
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least one of the following:
•

Post- procedure angiographic TIMI 0/1 flow in a major coronary artery or a side branch

with reference vessel diameter ≥2.0 mm which had TIMI 2-3 flow at baseline, or TIMI 2 flow in
a major coronary artery or a side branch with reference vessel diameter ≥3.0 mm which had
TIMI 3 flow at baseline or Type C dissection (NHLBI classification) or greater in the target
vessel.
•

New ECG changes (ST segment elevation or depression >0.1mV in 2 contiguous leads),

new pathologic Q-waves in ≥2 contiguous leads, or new persistent LBBB present on a post-PCI
ECG obtained at least 30 minutes and up to 48 hours post procedure in the absence of any
intervening coronary event between the time of the PCI procedure and the ECG showing
changes.

CABG-Related MI
CK-MB is the preferred serum biomarker and takes precedence over cardiac troponin. For
subjects with normal baseline biomarker level pre-CABG, peri-CABG MI requires a rise in CKMB to >10-fold the ULN (or a rise in troponin to >70 times MI Decision Limit/ULN when CKMB is unavailable) within 48 hours post-CABG. In addition to biomarker criteria, peri-CABG
MI requires at least one of the following:
•

A new substantial wall motion abnormality by cardiac imaging (CEC assessed),
except new septal and apical abnormalities. The CEC will have latitude in
determining whether a new wall motion abnormality is “substantial” in the context of
the clinical event.

•

New pathologic Q-waves in ≥2 contiguous leads or new persistent LBBB is present
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on post CABG ECG obtained day 3 post CABG, or hospital discharge, whichever
comes earlier in the absence of any intervening coronary event between the time of
the CABG procedure and the ECG
ISCHEMIA CKD
Two versions of MI will be adjudicated in ISCHEMIA-CKD: a primary definition and secondary
definition. Each definition includes a hierarchy of markers and threshold values as well as a set
of rules for diagnosing MI when one or more key elements of the medical record are missing.
The Primary Definition is based upon the Universal Definition of MI, but relies upon sitereported MI decision limits for troponin (which may or may not be the same as the manufacturer
99%URL), and has selected unique marker criteria for MI after PCI or CABG (Type 4a, 5).

The Secondary Definition is also based upon the Universal Definition of Myocardial Infarction,
but specifically uses the 99%URL from the assay manufacturer’s package insert (which may or
may not be the site’s MI decision limit) and uses the same supporting criteria (eg. angiographic
and ECG) as the UMI definition.
Spontaneous MI (Types 1, 2, 4b, 4c)
Diagnosis of spontaneous MI will be satisfied by a clinical setting consistent with acute
myocardial ischemia and any one or more of the following criteria:
Marker elevation, as outlined below and at least 1 of the following:
•

Symptoms of ischemia, usually lasting > 20 minutes in duration

•

New ischemic ST and/or T wave and/or Q-wave ECG changes, or new LBBB, as
described below
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•

Imaging evidence of new loss of viable myocardium in comparison to the baseline
imaging test

•

Angiographic evidence of intracoronary thrombus, stent thrombosis (4b) or high- grade
in-stent restenosis (≥50%) (4c)

Marker data not available and at least 2 of the following:
•

New ischemic ST and/or T wave and/or Q-wave ECG changes, or new LBBB, as
described below

•

Imaging evidence of new loss of viable myocardium in comparison to the baseline
imaging test

•

Angiographic evidence of intracoronary thrombus.

Autopsy evidence of a fresh myocardial infarction as stand-alone criterion
Spontaneous MI Marker Criteria
Troponin, including high-sensitivity troponin, is the preferred biomarker and takes precedence
over CK-MB for both definitions.
Primary Definition: Preferentially uses a troponin threshold value reported as MI Decision Limit
or the Upper Limit of Normal (ULN). Marker elevation is defined as troponin > ULN/MI
decision limit. If troponin is not done or not available, then CK-MB > ULN will qualify. If both
troponin and CKMB are not done or not available, then CK > 2 x ULN will qualify.
Secondary Definition: Preferentially uses a troponin threshold reported by the manufacturer,
namely, the manufacturer 99th percentile. Marker elevation is defined as troponin > 99th
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percentile. If the troponin 99th percentile is not reported, then troponin > ULN will qualify. If
troponin is not done or not available, then CK-MB > ULN will qualify. If both troponin and CKMB are not done or not available, then CK > 2 x ULN will qualify.
Spontaneous MI ECG Criteria
ECG criterion is considered to be met if any of the following:
ST elevation: New ST elevation at the J-point in two contiguous leads with the cutpoints:
≥ 0.2 mV in men >age 40 and ≥ 0.25mV in men <40 years or ≥ 0.15 mV in women in leads V2–
V3 and/or ≥ 0.1 mV in other leads, or new LBBB.

Any new Q-wave in leads V2–V3 ≥ 0.02 seconds or QS complex in leads V2 and V3 or Q-wave
≥ 0.03 seconds and ≥ 0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4–V6 in any two
leads of a contiguous lead grouping (I, aVL, V6; V4–V6; II, III, and aVF) or R-wave ≥ 0.04
seconds in V1–V2 and R/S ≥ 1 with a concordant positive T- wave in the absence of a
conduction defect.
ST depression and/or T-wave changes, new horizontal or down-sloping ST depression ≥ 0.05
mV in two contiguous leads; and/or T -wave inversion ≥ 0.1 mV in two contiguous leads. The
ST-T wave criteria only apply in the absence of findings that would preclude ECG analysis
such as LBBB, LVH with repolarization abnormalities, pre-excitation and pacemakers.
Silent MI
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This event includes evidence of new silent Q-wave MI detected during routine protocol or
clinically obtained ECG follow-up. Silent MI events will be classified as a type 1 MI.
Sudden death MI (Type 3)
MI events in which a presentation consistent with infarction is present but the patient dies before
the biomarkers are drawn or within the first few hours of the event before the biomarkers become
positive. Sudden unexpected cardiac death, including cardiac arrest, often with symptoms
suggestive of myocardial ischemia, accompanied by presumably new ST-segment elevation, or
new LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at
autopsy, but death occurring before blood samples could be obtained, or at a time before the
appearance of cardiac biomarkers in the blood.

PCI-Related MI (Type 4a)
Primary Definition
CK-MB is the preferred biomarker and takes precedence over troponin. For subjects with normal
baseline biomarker level pre-PCI, peri-PCI MI requires a rise in CK-MB to >5-fold the ULN (or
a rise in troponin to >35 times the MI Decision Limit/ULN, when CK- MB is unavailable) within
48 hours post-PCI. If pre-PCI cardiac markers (CKMB or cTn) are elevated, they must be stable
or falling as indicated by two samples at least 6 h apart. The post-PCI CKMB level should reflect
a rise of >20% over pre-PCI levels. In addition to biomarker criteria, peri-PCI MI requires at
least one of the following:
•

Post- procedure angiographic TIMI 0/1 flow in a major coronary artery or a side branch
with reference vessel diameter ≥2.0 mm which had TIMI 2-3 flow at baseline, or TIMI 2
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flow in a major coronary artery or a side branch with reference vessel diameter ≥3.0 mm
which had TIMI 3 flow at baseline or Type C dissection (NHLBI classification) or
greater in the target vessel.
•

New ECG changes (ST segment elevation or depression >0.1mV in 2 contiguous leads),
new pathologic Q-waves in ≥2 contiguous leads, or new persistent LBBB present on a
post-PCI ECG obtained at least 30 minutes and up to 48 hours post procedure in the
absence of any intervening coronary event between the time of the PCI procedure and the
ECG showing changes.

Secondary Definition
Elevation of troponin values >5 X 99th percentile URL within 48 hours post -PCI in patients
with normal baseline troponin values pre-PCI AND a rise of troponin values >20% if the

baseline values are elevated pre-PCI and are stable or falling. If the troponin 99th percentile is
not available, the MI Decision Limit / ULN may be used. If troponins are not available, CKMB
elevation >5 X ULN will be used.
In addition to biomarker criteria, peri-PCI MI requires at least one of the following:
•

Symptoms suggestive of myocardial ischemia (≥20 min)

•

New ischemic ST changes or new pathological Q waves. (see “ECG Criteria” above)
Note

•

the UMI definition uses ≥0.05 mV of STD whereas the ISCHEMIA definition uses ≥
0.1mV
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•

for PCI related ECG criteria

•

Angiographic evidence of a flow limiting complication, such as loss of patency of a side

•

branch, persistent slow-flow or no re-flow, embolization, or Type C dissection (NHLBI

•

classification) or greater in the target vessel.

•

Imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality.

CABG-Related MI (Type 5)
Primary Definition
CK-MB is the preferred serum biomarker and takes precedence over cardiac troponin. For
subjects with normal baseline biomarker level pre-CABG, peri-CABG MI requires a rise in CKMB to >10-fold the ULN (or a rise in troponin to >70 times MI Decision Limit/ULN when CK-

MB is unavailable) within 48 hrs post-CABG. In addition to biomarker criteria, peri-CABG MI
requires at least one of the following:
•

A new substantial wall motion abnormality by cardiac imaging (CEC assessed), except
new septal and apical abnormalities. The CEC will have latitude in determining whether a
new wall motion abnormality is “substantial” in the context of the clinical event.

•

New pathologic Q-waves in ≥2 contiguous leads or new persistent LBBB is present on
post CABG ECG obtained day 3 post CABG, or hospital discharge, whichever comes
earlier in the absence of any intervening coronary event between the time of the CABG
procedure and the ECG showing changes.

Secondary Definition
Elevation of troponin values >10 X 99th percentile URL within 48 hrs post -CABG in patients
Downloaded from http://ahajournals.org by on February 22, 2022

with normal baseline troponin values (≤ 99th percentile URL). If the troponin 99th percentile is
not available, the ULN may be used. If troponins are not available, CKMB elevation >10 X ULN
will be used. In addition to biomarker criteria, peri-CABG MI requires at least one of the
following:
•

New pathologic Q waves or new LBBB

•

Angiographic evidence of new graft or new native coronary artery occlusion.

•

Imaging evidence of new loss of viable myocardium.

